MBX Biosciences (MBX) Free Cash Flow (2023 - 2026)
MBX Biosciences (MBX) reported Free Cash Flow of -$20.6 million for Q1 2026, up 10.94% on a YoY basis from -$18.6 million in Q1 2025, and down 20.09% sequentially from -$17.2 million in Q4 2025.
MBX Biosciences (MBX) Free Cash Flow (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Free Cash Flow data on file, last reported at -$20.6 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 10.94% year-over-year to -$20.6 million; the trailing twelve-month figure through Mar 2026 stood at -$77.4 million (down 14.3% YoY), and the FY2025 full-year result was -$80.0 million, down 43.96% from the prior year.
- Free Cash Flow fell to -$20.6 million in Q1 2026, from -$17.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$11.0 million in Q1 2024 to a low of -$23.2 million in Q1 2025.
- A 4-year average of -$16.7 million and a median of -$16.7 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow tumbled 111.05% in 2025 and gained 10.94% in 2026, its largest moves.
- Tracing MBX's Free Cash Flow over 4 years: stood at -$11.3 million in 2023, then tumbled by 43.05% to -$16.1 million in 2024, then dropped by 6.58% to -$17.2 million in 2025, then decreased by 20.09% to -$20.6 million in 2026.
- Business Quant data shows MBX's Free Cash Flow at -$20.6 million in Q1 2026, -$17.2 million in Q4 2025, and -$21.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | MBX Biosciences | 2.96 Bn | 2.96 Bn | - | -20.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.65 Mn |
| Mar 31, 2026 | -20.65 Mn |
| Dec 31, 2025 | -17.19 Mn |
| Dec 31, 2025 | -17.19 Mn |
| Sep 30, 2025 | -21.94 Mn |
| Sep 30, 2025 | -21.94 Mn |
| Jun 30, 2025 | -17.67 Mn |
| Jun 30, 2025 | -17.67 Mn |
| Mar 31, 2025 | -23.18 Mn |
| Mar 31, 2025 | -23.18 Mn |
| Dec 31, 2024 | -16.13 Mn |
| Dec 31, 2024 | -16.13 Mn |
| Sep 30, 2024 | -15.38 Mn |
| Sep 30, 2024 | -15.38 Mn |
| Jun 30, 2024 | -13.07 Mn |
| Jun 30, 2024 | -13.07 Mn |
| Mar 31, 2024 | -10.98 Mn |
| Mar 31, 2024 | -10.98 Mn |
| Dec 31, 2023 | -11.28 Mn |
| Dec 31, 2023 | -11.28 Mn |